Lymphoma & Leukaemia Watch 41 - Novel approaches in T cell lymphoma

Dr Hannah Hsu BMedSci, MBBS, FRACP, FRCPA

Myelofibrosis Watch 1 - Treatment of Myelofibrosis

Dr Jacinta Perram MBBS(Hons), BA(Psych), BMedSc, MPH, FRACP, FRCPA, ECFMG Cert.

Lymphoma & Leukaemia Watch 40 - AMPLIFYing CLL

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 33 - Targeted anti-cancer agents & VTE

Dr Danny Hsu MBBS FRACP FRCPA

Advancing CAR T-cell therapy in Australia: The Referral Process and Patient Journey

These videos form the educational basis for a Research Review E-Learning Module, intended for Australian Health Professionals. Viewers may watch the videos, complete a short CPD quiz (see link below) and claim the time spent as a CPD activity. For more background information, read the previous Educational Series publication: Advancing CAR T-cell therapy in Australia: collaborative approaches for relapsed/refractory large B-cell lymphoma. We feature Dr Adam Bryant, Associate Professor Andrea Henden and Senior CAR-T cell Clinical Nurse Co-ordinator Cassie Abbott.

The video discussion focuses on the current CAR-T treating centres as at Jan 2025, additional centres may be added after this time.

ASH Highlights 2024 focus on Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

ASH CAR-T cell therapy Highlights 2024

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 39 - AN + AD for advanced stage Hodgkin Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 32 - Update on DOACs: New indications...and limitations

Dr Danny Hsu MBBS FRACP FRCPA

Blood Highlights 2024 - Focus Lymphoma & Leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 38 - Mantle cell lymphoma into the future

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 37 - Treatment of minimal residual disease in acute myeloid leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Professor Michael Dickinson discusses CAR T Cell Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Professor Michael Dickinson MBBS, D Med Sc, FRACP, FRCPA

Lymphoma & Leukaemia Watch 36 - Early stage follicular lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Lymphoma & Leukaemia Watch 35 - Deciding on allograft in NPM1 AML

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

EHA Highlights 2024

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 31 - Anticoagulation in cirrhosis ISTH SSC guidance

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 34 - Asciminib in chronic myeloid leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 30 - ASCO 2024: Update on key studies in multiple myeloma

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Haematology Watch 29 - Real world use of TPO-RA for ITP in the UK: TRAIT study

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 33 - 2 new treatments for T cell lymphomas

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 32 - Luspatercept vs epoetin alfa for treatment of anaemia in low risk MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Multiple Myeloma Watch 4 - t(11;14) myeloma have a B-cell like program and acquire numerous changes with resistance to venetoclax

Professor H. Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

ASH Highlights 2023

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 28 - Large B-cell lymphoma (LBOL) investigation & management

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 27 - Elranatamab (anti-BCMA BiTE) for Multiple Myeloma

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Haematology Watch 26 - Final study report of andexanet alfa for major bleeding with factor Xa inhibitors

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 30 - Allograft prolongs survival in TP53 mutated MDS

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 25 - Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 29 - Menin inhibitor revumenib in refractory acute leukaemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 24 - Predicting response in ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 27 - Zanubrutinib vs Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Haematology Watch 22 - Ruxolitinib is a valid treatment option in polycythaemia vera

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 21 - Risk of relapse in immune TTP and role of anti-CD20 therapy

Dr Danny Hsu MBBS FRACP FRCPA

Multiple Myeloma Watch 3 - NOVEL classes of therapy for relapsed and refractory myeloma; options other than CAR-T cells and bispecific antibodies!

Dr Adam Bryant MBBS (Hon) PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 25 - Bispecific Antibodies in B-Cell Lymphoma

Dr Monique Menzies Wojtowicz BAppSc(Pthy), MBBS(Hons), FRACP, FRCPA, MClinTRes

Multiple Myeloma Watch 2 - KCD based therapy versus AuSCT in myeloma

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Haematology Watch 19 - Non-malignant Haematology Highlights-Blood 2022

Dr Monique Menzies Wojtowicz BAppSc(Pthy) MBBS(Hons) FRACP, FRCPA

Multiple Myeloma Watch 1 - Myeloma Transplant and CAR-T guidelines

Professor Miles Prince MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD

Lymphoma & Leukaemia Watch 23 - Ph+ ALL; Decision making regarding allograft in CR1

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 22 - Updates in diffuse large B cell Lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Haematology Watch 18 - New Modalities for the management of ITP - ATRA and BTKi

Professor Harshal Nandurkar MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 21 - Updates in peripheral T cell lymphoma

Dr Shafqat Inam MBBS MMed FRACP FRCPA

Lymphoma & Leukaemia Watch 20 - POLARIX Study - A New Standard of Care in DLBCL?

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Haematology Watch 16 - Advancing treatment options for Paroxysmal Nocturnal Haemoglobinuria

Professor Harshal Nandurkar MBBS PhD FRACP

Lymphoma & Leukaemia Watch 18 - A Randomized Phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Lymphoma & Leukaemia Watch 17- Development of Second Generation BTKi in the Treatment of Lymphoid Cancers Part 2

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Haematology Watch 14 - ASH 2021 Abstracts Part 2; ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 15 - SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive CLL/SLL

Professor Constantine Tam MBBS (Hons) MD FRACP FRCPA

Lymphoma & Leukaemia Watch 14 - Recent local and international studies assessing pediatric ALL therapy adults <40y

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 13 - ASH 2021 Myeloid Disorders Abstracts Part 2

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Thrombosis & Haemostasis Watch 1 - Targeting coagulation factor XI for Thromboprophylaxis

Professor Harshal Nandurkar MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 12 - Advanced Stage Hodgkin Lymphoma: a case based approach

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 11 - ASH 2021 Myeloid Disorders Abstracts

Dr Bart Getta MBBS (HONS 1) (UNSW) GCERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology WATCH 10 BMT vs no BMT in Elderly MDS: A Biological Assignment Trial

Dr Bart Getta MBBS (HONS 1) (UNSW) GCert CLIN EPI (USYD) ECFMG FRACP FRCPA

Treatment approach and considerations in non-transplant eligible ndMM

Professor Simon Harrison MBBS, MRCP (UK), FRCPath (UK), FRACP, PhD

Haematology Watch 9 - Relapsed/Refractory Hodgkin Lymphoma: A Case Based Approach

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 8 - Vaccine - Induced Immune Thrombotic Thrombocytopenia

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 10 - New evidence to aid decision making in the treatment of older patients with AML (Part 1)

Dr Bartlomiej Getta MBBS (HONS 1) (UNSW) GRAD CERT CLIN EPI (USYD) ECFMG FRACP FRCPA

Haematology Watch 7 - DOAC in Obese Patients

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 7 - Updates in secondary CNS and limited stage diffuse large B cell Lymphoma

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 6 - Two updates in Burkitt & HGBCL

Dr Pietro Di Ciaccio BA LLB (Hons) MBBS FRACP FRCPA

Haematology Watch 6 - TPO receptor agonists in Pregnancy for ITP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 5 - Polatuzumab Vedotin & Relapsed/Refractory Diffuse Large B-cell Lymphoma

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 4 featuring a Q&A discussion Series 2

Dr Maya Latimer, Consultant Haematologist at the Canberra Region Cancer Centre, CRCC, the Canberra Hospital, ACT interviewing Professor Alessandra Ferrajoli, academic haematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson.

Haematology Watch 4 featuring a Q&A discussion Series 1

Haematology Watch 5 - What's New In ITP

Dr Danny Hsu MBBS FRACP FRCPA

ASH Highlights 2020

Professor Jeff Szer BMedSc MB BS FRACP

Haematology Watch 3 - Management of Thrombotic Microangiopathy in Pregnancy & Postpartum

Dr. Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 4 - Relapsed, Refractory Hodgkin Lymphoma-Update

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 3 - Follicular Lymphoma Treatment of Advanced Stage High Tumour Burden-A Recent Update

Prof. Mark Hertzberg MBBS PhD FRACP FRCPA

Haematology Watch 2 - 2020 ISTH Guidelines for Treatment of TTP

Dr Danny Hsu MBBS FRACP FRCPA

Lymphoma & Leukaemia Watch 2 - Hodgkin Lymphoma: two recent trial updates in first line therapy

Prof. Mark Hertzberg MBBS PhD FRACP FRCPA

Lymphoma & Leukaemia Watch 1 - Diffuse Large B-cell Lymphoma: two recent updates

Professor Mark Hertzberg MBBS PhD FRACP FRCPA

Managing patients with aHUS: key recommendations from an expert

Presented by Dr Danny Hsu.

Gaucher disease: A Haematologist's Perspective

Professor Jeff Szer

Gaucher disease - hyperferritinaemia, haematological malignancies and Parkinson's

Professor Jeff Szer

Treating CLL with novel therapies

Professor Peter Hillmen

Lymphoma & Leukaemia Watch 41 - Novel approaches in T cell lymphoma

Myelofibrosis Watch 1 - Treatment of Myelofibrosis

Lymphoma & Leukaemia Watch 40 - AMPLIFYing CLL

Haematology Watch 33 - Targeted anti-cancer agents & VTE

Advancing CAR T-cell therapy in Australia: The Referral Process and Patient Journey

ASH Highlights 2024 focus on Lymphoma & Leukaemia

ASH CAR-T cell therapy Highlights 2024

Lymphoma & Leukaemia Watch 39 - AN + AD for advanced stage Hodgkin Lymphoma

Haematology Watch 32 - Update on DOACs: New indications...and limitations

Blood Highlights 2024 - Focus Lymphoma & Leukaemia

Lymphoma & Leukaemia Watch 38 - Mantle cell lymphoma into the future

Lymphoma & Leukaemia Watch 37 - Treatment of minimal residual disease in acute myeloid leukaemia

Professor Michael Dickinson discusses CAR T Cell Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma & Leukaemia Watch 36 - Early stage follicular lymphoma

Lymphoma & Leukaemia Watch 35 - Deciding on allograft in NPM1 AML

EHA Highlights 2024

Haematology Watch 31 - Anticoagulation in cirrhosis ISTH SSC guidance

Lymphoma & Leukaemia Watch 34 - Asciminib in chronic myeloid leukaemia

Haematology Watch 30 - ASCO 2024: Update on key studies in multiple myeloma

Haematology Watch 29 - Real world use of TPO-RA for ITP in the UK: TRAIT study

Lymphoma & Leukaemia Watch 33 - 2 new treatments for T cell lymphomas

Lymphoma & Leukaemia Watch 32 - Luspatercept vs epoetin alfa for treatment of anaemia in low risk MDS

Multiple Myeloma Watch 4 - t(11;14) myeloma have a B-cell like program and acquire numerous changes with resistance to venetoclax

ASH Highlights 2023

Haematology Watch 28 - Large B-cell lymphoma (LBOL) investigation & management

Haematology Watch 27 - Elranatamab (anti-BCMA BiTE) for Multiple Myeloma

Haematology Watch 26 - Final study report of andexanet alfa for major bleeding with factor Xa inhibitors

Lymphoma & Leukaemia Watch 30 - Allograft prolongs survival in TP53 mutated MDS

Haematology Watch 25 - Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

Lymphoma & Leukaemia Watch 29 - Menin inhibitor revumenib in refractory acute leukaemia

Haematology Watch 24 - Predicting response in ITP

Lymphoma & Leukaemia Watch 27 - Zanubrutinib vs Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia

Haematology Watch 22 - Ruxolitinib is a valid treatment option in polycythaemia vera

Haematology Watch 21 - Risk of relapse in immune TTP and role of anti-CD20 therapy

Multiple Myeloma Watch 3 - NOVEL classes of therapy for relapsed and refractory myeloma; options other than CAR-T cells and bispecific antibodies!

Lymphoma & Leukaemia Watch 25 - Bispecific Antibodies in B-Cell Lymphoma

Multiple Myeloma Watch 2 - KCD based therapy versus AuSCT in myeloma

Haematology Watch 19 - Non-malignant Haematology Highlights-Blood 2022

Multiple Myeloma Watch 1 - Myeloma Transplant and CAR-T guidelines

Lymphoma & Leukaemia Watch 23 - Ph+ ALL; Decision making regarding allograft in CR1

Lymphoma & Leukaemia Watch 22 - Updates in diffuse large B cell Lymphoma

Haematology Watch 18 - New Modalities for the management of ITP - ATRA and BTKi

Lymphoma & Leukaemia Watch 21 - Updates in peripheral T cell lymphoma

Lymphoma & Leukaemia Watch 20 - POLARIX Study - A New Standard of Care in DLBCL?

Haematology Watch 16 - Advancing treatment options for Paroxysmal Nocturnal Haemoglobinuria

Lymphoma & Leukaemia Watch 18 - A Randomized Phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Lymphoma & Leukaemia Watch 17- Development of Second Generation BTKi in the Treatment of Lymphoid Cancers Part 2

Haematology Watch 14 - ASH 2021 Abstracts Part 2; ITP

Lymphoma & Leukaemia Watch 15 - SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive CLL/SLL

Lymphoma & Leukaemia Watch 14 - Recent local and international studies assessing pediatric ALL therapy adults <40y

Haematology Watch 13 - ASH 2021 Myeloid Disorders Abstracts Part 2

Thrombosis & Haemostasis Watch 1 - Targeting coagulation factor XI for Thromboprophylaxis

Lymphoma & Leukaemia Watch 12 - Advanced Stage Hodgkin Lymphoma: a case based approach

Haematology Watch 11 - ASH 2021 Myeloid Disorders Abstracts

Haematology WATCH 10 BMT vs no BMT in Elderly MDS: A Biological Assignment Trial

Dr Bart Getta MBBS (HONS 1) (UNSW) GCert CLIN EPI (USYD) ECFMG FRACP FRCPA

Treatment approach and considerations in non-transplant eligible ndMM

Haematology Watch 9 - Relapsed/Refractory Hodgkin Lymphoma: A Case Based Approach

Haematology Watch 8 - Vaccine - Induced Immune Thrombotic Thrombocytopenia

Lymphoma & Leukaemia Watch 10 - New evidence to aid decision making in the treatment of older patients with AML (Part 1)

Haematology Watch 7 - DOAC in Obese Patients

Lymphoma & Leukaemia Watch 7 - Updates in secondary CNS and limited stage diffuse large B cell Lymphoma

Lymphoma & Leukaemia Watch 6 - Two updates in Burkitt & HGBCL

Haematology Watch 6 - TPO receptor agonists in Pregnancy for ITP

Lymphoma & Leukaemia Watch 5 - Polatuzumab Vedotin & Relapsed/Refractory Diffuse Large B-cell Lymphoma

Haematology Watch 4 featuring a Q&A discussion Series 2

Haematology Watch 4 featuring a Q&A discussion Series 1

Haematology Watch 5 - What's New In ITP

ASH Highlights 2020

Haematology Watch 3 - Management of Thrombotic Microangiopathy in Pregnancy & Postpartum

Lymphoma & Leukaemia Watch 4 - Relapsed, Refractory Hodgkin Lymphoma-Update

Lymphoma & Leukaemia Watch 3 - Follicular Lymphoma Treatment of Advanced Stage High Tumour Burden-A Recent Update

Haematology Watch 2 - 2020 ISTH Guidelines for Treatment of TTP

Lymphoma & Leukaemia Watch 2 - Hodgkin Lymphoma: two recent trial updates in first line therapy

Lymphoma & Leukaemia Watch 1 - Diffuse Large B-cell Lymphoma: two recent updates

Managing patients with aHUS: key recommendations from an expert

Gaucher disease: A Haematologist's Perspective

Gaucher disease - hyperferritinaemia, haematological malignancies and Parkinson's

Treating CLL with novel therapies

Get Free publications straight to your inbox.